These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 23409060)
21. Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma. Pun MD; Gallazzi F; Ho KV; Watkinson L; Carmack TL; Iweha E; Li L; Anderson CJ Mol Pharm; 2024 Jun; 21(6):2960-2969. PubMed ID: 38680059 [TBL] [Abstract][Full Text] [Related]
22. Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator. Guo Y; Ferdani R; Anderson CJ Bioconjug Chem; 2012 Jul; 23(7):1470-7. PubMed ID: 22663248 [TBL] [Abstract][Full Text] [Related]
23. ImmunoPET Imaging of α White JB; Hu LY; Boucher DL; Sutcliffe JL Mol Imaging Biol; 2018 Feb; 20(1):103-113. PubMed ID: 28653240 [TBL] [Abstract][Full Text] [Related]
24. Improved Immuno-PET Imaging of HER2-Positive Tumors in Mice: Urokinase Injection-Triggered Clearance Enhancement of Ren Q; Mohri K; Warashina S; Wada Y; Watanabe Y; Mukai H Mol Pharm; 2019 Mar; 16(3):1065-1073. PubMed ID: 30633529 [TBL] [Abstract][Full Text] [Related]
25. Synthesis and Evaluation of New Bifunctional Chelators with Phosphonic Acid Arms for Gallium-68 Based PET Imaging in Melanoma. Gai Y; Sun L; Lan X; Zeng D; Xiang G; Ma X Bioconjug Chem; 2018 Oct; 29(10):3483-3494. PubMed ID: 30205001 [TBL] [Abstract][Full Text] [Related]
26. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034 [TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764 [TBL] [Abstract][Full Text] [Related]
28. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848 [TBL] [Abstract][Full Text] [Related]
29. Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. Hathi D; Chanswangphuwana C; Cho N; Fontana F; Maji D; Ritchey J; O'Neal J; Ghai A; Duncan K; Akers WJ; Fiala M; Vij R; DiPersio JF; Rettig M; Shokeen M Sci Rep; 2022 Jan; 12(1):30. PubMed ID: 34996933 [TBL] [Abstract][Full Text] [Related]
30. Ocak M; Beaino W; White A; Zeng D; Cai Z; Anderson CJ Cancer Biother Radiopharm; 2018 Mar; 33(2):74-83. PubMed ID: 29634417 [TBL] [Abstract][Full Text] [Related]
31. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900 [TBL] [Abstract][Full Text] [Related]
33. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Shokeen M; Anderson CJ Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674 [TBL] [Abstract][Full Text] [Related]
34. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508 [TBL] [Abstract][Full Text] [Related]
36. Enantiopure bifunctional chelators for copper radiopharmaceuticals--does chirality matter in radiotracer design? Singh AN; Dakanali M; Hao G; Ramezani S; Kumar A; Sun X Eur J Med Chem; 2014 Jun; 80():308-15. PubMed ID: 24793881 [TBL] [Abstract][Full Text] [Related]
37. Development of New CD38 Targeted Peptides for Cancer Imaging. Zheleznyak A; Tang R; Duncan K; Manion B; Liang K; Xu B; Vanover A; Ghai A; Prior J; Lees S; Achilefu S; Kelly K; Shokeen M Mol Imaging Biol; 2024 Aug; 26(4):738-752. PubMed ID: 38480650 [TBL] [Abstract][Full Text] [Related]
38. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283 [TBL] [Abstract][Full Text] [Related]
39. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules. Qi S; Hoppmann S; Xu Y; Cheng Z Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of a (64)Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing alphavbeta3 integrin. Jiang L; Kimura RH; Miao Z; Silverman AP; Ren G; Liu H; Li P; Gambhir SS; Cochran JR; Cheng Z J Nucl Med; 2010 Feb; 51(2):251-258. PubMed ID: 20124048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]